A Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis

• Status: Completed
• Trial end date: 2021-01-20
• Target enrollment: 0
• Participant gender: All

Summary

An open label study investigating the efficacy and safety, and pharmacokinetic (PK) profile of ANB019 in subjects with generalized pustular psoriasis

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AnaptysBio, Inc.

Criteria

Inclusion Criteria:

• Diagnosis of active GPP

• Total JDA score of at least 6 and erythema with pustules accounting for at least 10% or a moderate severity score on GPPPGA

• Must be candidates for systemic therapy or phototherapy

Exclusion Criteria:

• Erythrodermic, guttate psoriasis, drug induced GPP

• Any other ongoing inflammatory disease that interfere with the Investigator's ability to evaluate the subject's response to therapy

• History of recurrent or chronic infection

• ongoing use of psoriasis prohibited medication

Other protocol-defined inclusion/exclusion criteria may apply